Biogen Idec (NASDAQ: BIIB) reported Q4 EPS of $4.09, $0.31 better than the analyst estimate of $3.78. Revenue for the quarter came in at $2.6 billion versus the consensus estimate of $2.64 billion.

Biogen Idec sees FY2015 EPS of $16.60-$17.00, versus the consensus of $16.37.

For earnings history and earnings-related data on Biogen Idec (BIIB) click here.